Skip to main content

Acute Schizophrenia

Neurology
6
Pipeline Programs
3
Companies
6
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
5
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

On Market (1)

Approved therapies currently available

Otsuka
REXULTIApproved
brexpiprazole
Otsuka
Atypical Antipsychotic [EPC]oral2015
630M Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
4 programs
4
1
BrexpiprazolePhase 3Small Molecule1 trial
OPC-34712Phase 31 trial
OPC-34712 [Brexpiprazole] High DosePhase 31 trial
OPC-34712FUM/ Brexpiprazole fumaratePhase 31 trial
Active Trials
NCT01668797Completed524Est. Feb 2015
NCT01393613Completed674Est. Feb 2014
NCT01396421Completed636Est. Jan 2014
+1 more trials
Chengdu Kanghong Pharmaceutical Group
1
Hydrochloride Carliprazine capsulesPhase 31 trial
Active Trials
NCT06589817Not Yet Recruiting376Est. Dec 2026
Reviva Pharmaceuticals
1 program
RP5063PHASE_21 trial
Active Trials
NCT01490086Completed234Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Chengdu Kanghong Pharmaceutical GroupHydrochloride Carliprazine capsules
OtsukaOPC-34712FUM/ Brexpiprazole fumarate
OtsukaBrexpiprazole
OtsukaOPC-34712
OtsukaOPC-34712 [Brexpiprazole] High Dose
Reviva PharmaceuticalsRP5063

Clinical Trials (6)

Total enrollment: 2,894 patients across 6 trials

NCT06589817Chengdu Kanghong Pharmaceutical GroupHydrochloride Carliprazine capsules

A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia

Start: Oct 2024Est. completion: Dec 2026376 patients
Phase 3Not Yet Recruiting
NCT05325645OtsukaOPC-34712FUM/ Brexpiprazole fumarate

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Start: Jul 2022Est. completion: Mar 2026450 patients
Phase 3Recruiting
NCT01668797OtsukaBrexpiprazole

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Start: Oct 2012Est. completion: Feb 2015524 patients
Phase 3Completed

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

Start: Jul 2011Est. completion: Feb 2014674 patients
Phase 3Completed
NCT01396421OtsukaOPC-34712 [Brexpiprazole] High Dose

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

Start: Jul 2011Est. completion: Jan 2014636 patients
Phase 3Completed

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Start: Dec 2011Est. completion: Mar 2013234 patients
Phase 2Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,894 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.